Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2012

Goldberg Sarah B, Supko Jeffrey G, Neal Joel W, Muzikansky Alona, Digumarthy Subba, Fidias Panos, Temel Jennifer S, Heist Rebecca S, Shaw Alice T, McCarthy Patricia O, Lynch Thomas J, Sharma Sreenath, Settleman Jeffrey E, Sequist Lecia V

Abstract excerpt

INTRODUCTION: This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer. METHODS: Patients with prior clinical benefit from an e...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Everolimus

Share to Hydroxychloroquine

Share to Immunosuppressive Agents

Share to Maximum Tolerated Dose

Share to Sirolimus

Share to Tissue Distribution

Source

Open in PubMed Open full text

Identifiers

PMID: 22878749
DOI: 10.1097/JTO.0b013e318262de4a
PMCID: PMC3791327

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22878749-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.PMID 22878749Read ↗

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.Semantic proximity Read ↗

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Semantic proximity Read ↗

Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy.Semantic proximity Read ↗

Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapySemantic proximity Read ↗

A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.Semantic proximity Read ↗

Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.Semantic proximity Read ↗

Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.